phate (cGMP) system [2] [3] [4] . Recent studies have demonfrom the prohormone of ␣-human atrial natriuretic peptide strated that after proteolytic release of the C-terminal proANP(79-98) [5, 6] . These fragments circulate in ani-
Results. In patients with kidney disease and normal renal function without proteinuria, circulating proANP(1-30) and mal species and healthy humans exhibiting circadian proANP(31-67) increased 2.8-fold and 6.5-fold, respectively.
variations inversely related to the levels of atrial blood Urinary excretion of proANP(31-67) increased by a factor of pressure [7] . Furthermore, it has been demonstrated that 7 .7 in these patients, whereas proANP(1-30) was not affected.
N-terminal fragments have biological functions that are
Patients with impaired renal function had a dramatic increase of urinary proANP(31-67) excretion even before serum creatiqualitatively similar to ␣-ANP [8] [9] [10] . No data are availnine levels started to rise. The progression of renal failure able regarding the activity of proANP . Unlike the caused a significant rise of circulating proANP(1-30) (4.3-fold) atria, the kidney appears to secrete an atriapeptin (AP)-and proANP(31-67) (3.0-fold) compared with patients with like protein that was detected in the cortical tubule fracnormal renal function. Urinary excretion of proANP peptides tion [11] . It was further demonstrated that normal rat significantly increased, particularly when the serum creatinine level was Ͼ5.0 mg/dL [proANP kidney expresses ANP mRNA [12] . Urodilatin-proANP 
Urodilatin being synthesized in the distal tubular region
Conclusions. Plasma concentrations and urinary excretion may be transported as a paracrine factor to the collecting of proANP(1-30) and proANP(31-67) are affected by kidney disease and function, but not by proteinuria per se. It is product, where it exerts its suppressing effect on the sodium posed that the diseased kidney increases early urinary excretion reabsorption inducing diuresis and natriuresis [13, 14] .
of proANP fragments to participate in the regulation of renal In particular, previous pharmacological studies have function as well as sodium and water excretion.
reported that proANP(31-67) promotes sodium excretion and affects vasodilation in the rat [10] , dog [15] , and human [16] . However, the mechanisms for the natriuretic Atrial natriuretic peptide [proANP(99-126); ␣-ANP] actions of proANP(31-67) are not completely defined. It was discovered as a cardiac hormone in which the 126 is suggested that the inhibition of the sodium-potassiumamino acid prohormone proANP(1-126) is stored in ATPase in both the kidney medulla and cortex is mediated by prostaglandin E2 [17] . A recently published experimental study in anesthetized dogs with a single intact portant hormonal mechanism involved in the regulation (normal serum creatinine and creatinine clearance) without a loss of urinary protein. These individuals had polyof body fluid balance.
Clinical studies on circulating N-terminal proANP cystic kidney disease or glomerulonephritis with complete remission after immunosuppressive therapy. fragments have mainly focused on patients with cardiac disorders. It was found that their plasma concentrations As a control group, 16 healthy volunteers from our hospital staff with a mean Ϯ SD age of 36 Ϯ 10 years correlated significantly with echocardiographic measurements of left ventricular structure and performance, the (range 23 to 54) were studied. No drugs were taken by these volunteers, except hormonal contraceptives by function of aortic and mitral valves, and mortality [19] [20] [21] [22] . Our group has recently investigated the influence of perisome females. odic circulatory volume expansion on plasma concentraAnalytical methods tions of different proANP fragments in a large group of patients undergoing regular hemodialysis treatment [23] .
Blood samples were obtained by puncture of an antecubital vein after a supine rest of at least 10 minutes. It was found that circulating proANP fragments are influenced by a variety of factors such as end-stage renal All samples were collected in chilled tubes containing ethylenediaminetetraacetic acid (EDTA) and aprotinin, disease, hemodialysis treatment per se, dialyzer membrane material, cardiac dysfunction, and/or hypertension.
immediately placed on ice, and centrifuged within 10 minutes. Plasma was separated and stored at Ϫ70ЊC until N-terminal proANP fragments have been determined mainly in the circulation. To date, urinary excretion of analysis. Urine samples of a 24-hour collected urine were also stored at Ϫ70ЊC until analysis. Plasma and urine proANP peptides has been investigated only in healthy humans [24] and dogs [25] . No systematic data are availconcentrations of proANP(1-30) and proANP(31-67) were determined by competitive and specific enzyme able about proANP fragments in nondialyzed patients with renal disease. Therefore, the present study was perimmunoassays [26] . The detection limits were 2.5 and 10 pmol/L. Cross-reactivity with proANP(1-98) was 68% formed to evaluate proANP fragments in the plasma and urine of 121 patients with different kidney diseases, and 108%, respectively, and no cross-reactivity was observed with proANP(79-98) or proANP(99-128). different degrees of impairment of renal function, and different degrees of urinary protein excretion as comStatistical analysis pared with healthy controls.
Results are given as mean Ϯ SD. Statistical analyses were performed using the Student t test of paired data METHODS when comparing differences between consecutive values Patients in the same individuals. Differences between groups were compared by unpaired t test. Simple correlation We studied 121 patients, 63 women and 58 men, with various renal diseases. Patient ages ranged from 18 to analysis was performed by one-way analysis of variance (ANOVA). A P value less than 0.05 was considered 88 years, with a mean Ϯ SD age of 54 Ϯ 16 years. The etiology of kidney disease was membranous glomerulosignificant. nephritis (N ϭ 12), rapid proliferative glomerulonephritis (N ϭ 10), IgA nephritis (N ϭ 9), minimal change RESULTS glomerulonephritis (N ϭ 7), Henoch Schö nlein glomeruPlasma concentrations and urinary excretion of lonephritis (N ϭ 2), focal segmental glomerulosclerosis proANP(1-30) and proANP(31-67) in patients with (N ϭ 9), diabetic nephropathy (N ϭ 15), hypertensive renal disease but preserved renal function nephropathy (N ϭ 8), analgesic nephropathy (N ϭ 8), polycystic kidney disease (N ϭ 6), miscellaneous (N ϭ In healthy volunteers (N ϭ 16), the plasma concentrations of proANP(1-30) and proANP(31-67) varied be-18), or shrunken kidney of unknown etiology (N ϭ 17). In all patients, blood was drawn for blood chemistry, tween 0.23 and 0.41 nmol/L. The urine concentrations of proANP(1-30) and proANP(31-67) were 88 Ϯ 39 and and urine was collected at 24 hours for analysis. Fortythree patients had a normal serum creatinine; in the 181 Ϯ 130 nmol/24 hours, respectively. In patients with renal disease but preserved renal function and without remaining 78 patients, the serum creatinine level ranged between 1.3 and 6.7 mg/dL. In 29 patients, serum creatiproteinuria (N ϭ 19), plasma levels of proANP(1-30) were 2.8-fold (P Ͻ 0.001) and of proANP(31-67) were nine was between 1.3 and 2.5 mg/dL. In 39 patients, it was between 2.5 and 5.0 mg/dL, and in 10 patients, serum 6.5-fold (P Ͻ 0.0001) higher than in the control group (Fig. 1A ). Urinary excretion of proANP(1-30) was not creatinine was Ͼ5.0 mg/dL. Urinary protein loss was Ͻ0.15 g/24 hours in 23 patients, between 0.15 and 1.0 different between both groups, but urinary proANP(31-67) elimination was 7.7-fold (P Ͻ 0.0001) elevated as g/24 hours in 41 patients, between 1.0 and 3.0 g/24 hours in 31 patients, and higher than 3.0 g/24 hours in 26 pacompared with the control group (Fig. 1B) . In the control group, the mean plasma level of proANP(31-67) was tients. Overall, 19 patients had normal renal function slightly lower than proANP(1-30), whereas in the group tion significantly increased as soon as serum creatinine levels exceeded 2.5 mg/dL and were distinctly higher when of patients with renal disease, the mean plasma concentration of proANP(31-67) was 1.7-fold higher than proserum creatinine levels were above 5.0 mg/dL (Fig. 2B ). Circulating proANP(1-30) maximally increased 4.3-fold, ANP . In both of the groups, the urine excretion of proANP(31-67) was significantly higher than the urine and proANP(31-67) rose 3.0-fold. Urinary proANP(1-30) excretion maximally increased up to 26-fold, whereas uriexcretion of proANP(1-30), twofold for the control group (P Ͻ 0.006), but 13.8-fold for the group of patients nary proANP(31-67) elimination rose 8.4-fold in the group of patients with serum creatinine levels over 5.0 mg/dL. with renal disease (P Ͻ 0.0001).
Plasma concentrations and urinary excretion of
Plasma concentration and urinary excretion of proANP(1-30) and proANP(31-67) in patients with proANP(1-30) and proANP(31-67) in patients with renal disease and impaired renal function renal disease and different degrees of proteinuria Plasma concentration and urinary excretion of proPlasma concentration and urinary excretion of pro-ANP(1-30) and proANP(31-67) were determined in pa-ANP(1-30) and proANP(31-67) were determined in patients with renal disease according to their daily urinary tients with renal disease and different degrees of renal failure according to the serum creatinine level (range protein excretion rates (range 0 to 20.3 g/24 hours). There was no significant difference for circulating proANP(1-30) 0.7 to 6.8 mg/dL). Figure 2 demonstrates that patients with a serum creatinine in the normal range had the or proANP(31-67) whether the patients had no proteinuria or were severely proteinuric (Fig. 3A) . A signifilowest plasma concentrations and urinary excretion of proANP(1-30) and proANP(31-67). Progression of renal cantly (P Ͻ 0.05) higher urinary excretion of proANP(1-30) was found in patients when proteinuria exceeded 1.0 failure was associated with a consecutive rise of plasma proANP(1-30) and proANP(31-67) concentrations. Howg/24 h (Fig. 3B) . Urinary excretion of proANP(31-67) increased according to the rise of proteinuria, but the ever, urinary proANP(1-30) and proANP(31-67) excre- protein loss was 0.1 Ϯ 0.1 g/24 hours in the nonproteinuric group and 5.3 Ϯ 5.2 g/24 hours in the proteinuric group difference was not statistically significant until the uri-(P Ͻ 0.0001). Circulating proANP(1-30) and proANP(31-nary protein loss was Ͼ5.0 g/24 h. (Fig. 3B) . However, 67) did not differ between the two groups (Fig. 4A ). No patients with proteinuria between 1.0 and 3.0 g/24 hours significant difference was also found for urinary excretion and those with a urinary protein loss Ͼ5.0 g/24 hours of proANP(1-30) and proANP(31-67) between the two had significantly higher serum creatinine levels (2.9 Ϯ groups (Fig. 4B ). 1.9 and 2.6 Ϯ 1.6 mg/dL) than patients with proteinuria Ͻ1.0 g/24 hours and Ͻ0.15 g/24 hours (2.3 Ϯ 1.5 and Correlations 1.7 Ϯ 0.9 mg/dL). Urinary excretion of proANP proANP and proANP(31-67) in plasma and urine, increased by a maximum of 4.4-fold. Urinary excretion and their correlation to serum creatinine levels and proteinof proANP(31-67) was elevated by a maximum of 2.4-uria. Overall, there was a good correlation between plasma fold in the group of patients with proteinuria Ͼ3.0 g/24 concentrations of proANP(1-30) and proANP(31-67) hours.
(correlation coefficient R ϭ 0.9, P Ͻ 0.0001), as well as Plasma concentration and urinary excretion of between their respective urinary excretion rates (R ϭ 0.8, proANP fragments in patients with normal serum P Ͻ 0.0001). No correlation was found between circulating creatinine: Nonproteinuric versus proteinuric patients proANP(1-30) and urinary excretion of proANP(1-30), but circulating proANP(31-67) significantly correlated Figure 4 shows plasma levels and urinary excretion of with proANP(31-67) urine excretion (R ϭ 0.5, P Ͻ proANP(1-30) and proANP(31-67) in patients with a 0.0001). The serum creatinine levels of the patients correnormal serum creatinine value and urinary protein excrelated well with both plasma concentrations and urinary tion Ͻ0.15 g/24 hours (N ϭ 19) as compared with elimination of proANP(1-30) and proANP(31-67) (R bepatients with a normal serum creatinine value but proteinuria Ͼ1.0 g/24 hours (N ϭ 17). Mean Ϯ SD urinary tween 0.4 and 0.6, P Ͻ 0.0001). However, urinary protein loss did not correlate with either plasma levels nor with quantitation of the relative amounts would be only possible if the major circulating peptides are unequivocally urinary excretion of proANP(1-30) or proANP(31-67).
Plasma concentrations and urinary excretion of proidentified. We investigated 121 patients with renal disease and ANP and proANP(31-67) and their correlation to urinary sodium excretion, systolic and diastolic blood different degrees of renal failure as well as different degrees of urinary protein loss. In addition to the plasma pressure. Urinary sodium excretion did not correlate with proANP(1-30) or proANP(31-67) in either plasma concentrations of proANP(1-30) and proANP(31-67), we also determined their respective urinary excretion nor urine. Systolic blood pressure slightly correlated with plasma proANP(31-67) concentration (R ϭ 0.3, P Ͻ 0.01) expressed as nmol/24 h. Since ANP is reportedly synthesized in the kidneys [11, 12] and some of its forms may and urinary excretion of proANP(1-30) (R ϭ 0.3, P Ͻ 0.03), whereas diastolic blood pressure did not correlate have important autocrine or paracrine regulatory function [11] , the urinary excretion of proANP fragments with either of the propeptides in plasma or urine. The correlation between diastolic blood pressure and urinary seemed to be of interest. The present study reveals that patients with renal sodium excretion was slightly significant (R ϭ 0.3, P Ͻ 0.05), but not for the systolic blood pressure.
disease but normal kidney function and no proteinuria had significantly higher plasma concentrations of pro-ANP(1-30) and proANP(31-67) than healthy controls DISCUSSION (Fig. 1A) . Their urinary excretion of proANP(31-67) Some fragments that derive from the N-terminus of was considerably elevated when compared with healthy proANP, namely proANP(1-30) and proANP(31-67), subjects (Fig. 1B) . Interestingly, the mean plasma conhave been shown to exert biological functions qualitacentration of proANP(31-67) was only 1.7-fold higher tively similar to the C-terminal ␣-ANP [8] [9] [10] . The major than the mean plasma concentration of proANP(1-30), stimulus for prohormone synthesis and ANP release is as compared with a 13.8-fold higher urinary excretion atrial stretch caused by volume overload [2] [3] [4] . It was of proANP(31-67) than that of proANP(1-30). It seems shown that proANP(31-67) levels determined by radiothat in the diseased kidney, although renal function is immunoassay were a better guide to small changes in normal, there are factors that determine proANP synthesalt and water metabolism than levels of ␣-ANP. In persis, specifically the renal clearance and degradation of sons with chronic heart failure, serum levels of prothe peptides. ANP(31-67) were reportedly the most sensitive indicator None of the patients with normal renal function in our of the degree of disease, allowing differentiation of indistudy had evidence for volume overload. Mean sodium viduals in the New York Heart Association class I from excretion was 188 Ϯ 128 mmol/24 hours and was higher normal healthy individuals [19] [20] [21] [22] . Patients with endcompared with healthy controls (119 Ϯ 41 mmol/24 stage renal disease undergoing regular hemodialysis hours). Their mean arterial blood pressure was within treatment have markedly increased plasma concentranormal ranges (systolic blood pressure 127 Ϯ 15 mm Hg, tions of proANP fragments [23] . Whereas hemodialysis diastolic blood pressure 80 Ϯ 9 mm Hg), but 6 out of never corrects the defect in the metabolism of these pep-19 patients received antihypertensive medication (5 patides [23], successful kidney transplantation decreases tients took 1 drug and 1 patient took 3 drugs). Schmid the circulating levels of ␣-ANP, proANP(31-67), and et al investigated hypertensive patients with polycystic proANP(1-98) within the first 24 hours after surgery, kidney disease who were on a low-sodium and highand the levels return to normal within 7 to 10 days [27].
sodium diet [28] ; their natriuresis-blood pressure curve However, until now there have been no systematic data showed an upward shift (resetting) and a positive slope available that focus on proANP fragments in patients (sodium sensitivity) associated with an exaggerated rewith different degrees of renal disease before hemodialysponse of ANP to sodium loading. The resetting of the sis is instituted. Furthermore, as our assays are suitable natriuresis-blood pressure relationship and the increased for different biological specimen, urinary excretion was blood pressure sensitivity to sodium was observed irreincluded in our studies.
spective of whether the glomerular filtration rate was Regarding the specificity of the immunoassays used, normal or reduced [28] . Another five patients were actuboth also recognize proANP(1-98) and possibly other pepally treated with immunosuppressive agents. One patient tides derived from this precursor as long they contain the received cyclophosphamide. Another patient was treated respective epitopes from the regions (1-30) and (31-67).
with cyclosporine, and three patients received low-dose However, since the levels measured are not well correprednisone. Finally, the age of this patient population lated, we conclude that the majority of the immunoreacwas significantly higher than in healthy controls (50 Ϯ tive peptides are recognized in only one of the assays.
17 vs. 36 Ϯ 10 years, P Ͻ 0.001). Thus, we cannot exclude Species that contain both epitopes and are measured in that factors such as hypertension, immunosuppressive treatment, or the patients' age could be responsible for both assays represent only a small fraction. A detailed the observed elevated plasma concentrations and urinary by the respective serum creatinine level. According to our findings, we assume that with the rise of circulating excretion of proANP peptides in patients with renal disease but normal kidney function.
proANP fragments caused by progressive renal failure, the diseased kidney may increase the clearance rate of Ritter, Needleman, and Greenwald demonstrated the de novo synthesis of an atriapeptin (AP)-like protein these peptides and probably also synthesizes proANP peptides in an attempt to increase diuresis. (AP126ir) in neonatal rat kidney cultures [11] . Unlike the atria, kidney cells appear to secrete AP solely by
In the present study, we further investigated whether the amount of urinary protein loss determines plasma constitutive means. In primary adult rat kidney cultures, most of the AP126ir was detected in the cortical tubule concentrations and urinary excretion of proANP peptides. Proteinuria ranged between 0 and 20.3 g/24 hours, fraction, demonstrating that these cells could secrete AP126ir. It was hypothesized that the renal AP may be but the amount of urinary protein loss did not significantly affect the levels of circulating proANP fragments as important as an autocrine or paracrine regulator of renal function [11] . Also, Greenwald et al demonstrated (Fig. 3A) . Urinary excretion of proANP(1-30) significantly increased when proteinuria was higher than 1.0 that normal rat kidney expresses ANP mRNA [12] . This study further substantiates the synthesis of ANP in the g/24 hours, and urinary excretion of proANP(31-67) was significantly elevated when proteinuria exceeded 3.0 g/24 mammalian kidney. Unlike the mammalian heart, the kidney may contain two distinct ANP gene transcripts hours (Fig. 3B ). This can be explained by differences in renal function. In patients with normal serum creatinine, [12] . Our results support the hypothesis that proANP is synthesized in the kidney and indicate that a renal ANP the amount of urinary protein loss did not significantly relate to the plasma concentration or urinary excretion secretion serves as an adaptive mechanism to preserve renal function in kidney disease.
of proANP(1-30) or proANP(31-67) (Fig. 4) . Overall, urinary protein loss did not correlate with any of the In 1988, Winters et al demonstrated that chronic renal failure was associated with significantly increased circulaproANP fragments in plasma or urine. Although N-terminal fragments of the pro-ANP are ting concentrations of proANP(1-30) and proANP(31-67) compared with healthy controls [5] . However, the authought to have biological function such as natriuresis and diuresis, the sodium excretion (mmol/day) of the thors have investigated 15 patients with high-grade renal impairment only [5] . Our group recently published a study patients did not correlate with either proANP(1-30) or proANP(31-67) excretion or with their respective plasma on proANP peptides in a larger group of patients undergoing regular hemodialysis treatment [23] . We demonconcentrations. Systolic blood pressure was 137 Ϯ 20 mm Hg (mean Ϯ SD) and correlated slightly with plasma strated that end-stage renal failure is associated with increasing plasma concentrations of proANP(1-30) and levels of proANP(31-67) and urinary excretion of pro-ANP(1-30). Diastolic blood pressure was 81 Ϯ 9 mm Hg proANP(31-67) [23] . Our present study shows that with the progression of renal failure the maximal relative in-(mean Ϯ SD) and did not correlate with any of the proANP peptides. Diastolic blood pressure, however, crease was slightly higher for circulating proANP(1-30) than for proANP(31-67) (4.3-vs. 3.0-fold). However, the showed a weak but significantly positive correlation to urinary sodium excretion. highest plasma levels measured were much lower than predialytic plasma concentrations of patients with endIn conclusion, plasma concentrations and urinary excretion of proANP(1-30) and proANP(31-67) are afstage renal failure undergoing regular hemodialysis treatment. The increase of urinary excretion of proANP fected by renal failure, but not by proteinuria per se.
Other factors such as hypertension, immunosuppressive and proANP(31-67) was not significant until serum creatinine exceeded 2.5 mg/dL (Fig. 2B ). In patients with agents, and/or age of the patients also could affect plasma and urinary proANP peptides. However, it is presumed high-grade renal failure (serum creatinine Ͼ5.0 mg/dL), urinary excretion of proANP fragments was markedly that the diseased kidney increases urinary excretion of proANP peptides to participate in the regulation of renal elevated, proANP(1-30) 26-fold, but proANP(31-67) only 8.4-fold (Fig. 2B) . In end-stage renal failure, the function and possibly to synthesize atrial natriuretic prohormone. It is hypothesized that the early and dramatic increased concentrations of circulating proANP fragments in part may reflect reduced renal clearance. Howincrease of circulating and excreted fragments of pro-ANP in renal pathology and deteriorating renal function ever, we have demonstrated that simultaneously with the rise of proANP fragments in the circulation, the might exert a mechanism of counter-regulation. These peptides could actually compensate for vascular and rerespective urinary excretion also increased. Overall, we found a highly positive correlation between the plasma nal effects of messengers like catecholamines, angiotensin, and endothelin, which all increase because of renal concentrations of proANP(1-30) and proANP(31-67), as well as between their urinary excretions. Plasma concenpathology. This hypothesis seems reasonable, since it has recently been shown that the administration of protrations and urinary excretion of proANP peptides were also correlated to the degree of renal failure expressed ANP(31-67) helps to counter-regulate deteriorating re-sion of the gene for atrial natriuretic factor. Am J Physiol 263:F974-nal function and tubular damage in rats with acute renal F978, 1992 failure [29] . Thus, our findings on fragments of proANP
